Draupnir Bio
Developer of oral, small molecule degrades for extracellular disease-causing proteins.
1
Funding Rounds
$13.0m
Money raised
Overview
Developer of oral, small molecule degrades for extracellular disease-causing proteins.
- Website:
- Business model: B2B
- Headquarters: Copenhagen
- Social accounts: linkedin
Funding series
Funding Series Analysis
The company Draupnir Bio has raised a total of $13m in funding over 1 rounds.
Key Insights:
- Draupnir Bio July 2024 Seed Funding Round: $13m
Draupnir Bio July 2024 Seed Funding Round
$13m